"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

GSK will also be responsible for success-based milestone payments as well as tiered royalties for efimosfermin owed to Novartis Pharma AG. Efimosfermin is an investigational, once-monthly subcutaneous ...

GSK’s new asset is taken once monthly via a subcutaneous injection. Efimosfermin is a long-acting variant of fibroblast growth factor 21 (FGF21) that is designed to regulate key metabolic ...

GSK believes that efimosfermin has the potential to address more advanced stages of SLD, including alcohol-related liver disease (ALD). It plans to develop it as a monotherapy as well as in ...

Only a few days out of the European Association for the Study of the Liver annual meeting, the metabolic dysfunction-associated steatohepatitis (MASH) space continues to grab headlines, with GSK plc ...

GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14. The agreement includes a $1.2 billion ...

Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totalling $800million. Efimosfermin is a phase III-ready, ...

GSK stock dips 0.6% after six-session gain streak. ... GSK is also set to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2B in cash.

GSK plc announced the completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals. Efimosfermin is a phase III-ready, potential best-in-class investigational ...